GBMS yields 200000000.00% · ABBV yields 3.12%● Live data
📍 GBMS pulled ahead of the other in Year 1
Combined, GBMS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GBMS + ABBV for your $10,000?
Global Materials & Services, Inc., a fire protection company, specializes in fire prevention and fire containment. It develops, manufactures, and markets a line of interior and exterior fire retardant chemicals and products; and provides fire resistive finishing services, through its textile processing center for commercial users. The company also designs new technology for future fire resistive applications that are being mandated by local, state, and governmental agencies. In addition, Global Materials & Services offers retails products, which include 3-in-1 Hero, a product for upholstery, draperies, carpets, and various fabrics to make them fire retardant and inhibit microorganisms, such as dust mites; and TreeSafe, a product that prevents flames from occurring or spreading on Christmas trees. The company was organized in 1992. It was formerly known as American Fire Retardant Corporation and changed its name to Global Materials & Services, Inc. in January 2005. Global Materials & Services is headquartered in Santee, California.
Full GBMS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.